Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Getty Realty Fourth Quarter 2025 Earnings Call - Accretive deployment: ~$270M at 7.9% initial yield with $100M pipeline
Getty delivered steady income and an aggressive deployment push in 2025. Annualized base rent rose nearly 12% and AFFO per share finished the year at $20.43, with Q4 AFFO $0.63, up 5% year over year. ...
- Getty invested approximately $270 million in 2025 at a weighted initial cash yield of 7.9%.
- AFFO per share: Q4 2025 was $0.63, up 5% vs Q4 2024; full year AFFO per share was $20.43, up 3.8% year over year.
- Company reaffirmed 2026 AFFO per share guidance of $20.48 to $20.50, noting that this guide excludes prospective investment and capital activity.
- +12 more takeaways
Onity Group Q4 2025 Earnings Call - Record originations offset servicing runoff; $120M valuation allowance release boosts book value
Onity delivered a bumper finish to 2025, led by record-funded originations that powered origination adjusted pre-tax income higher even as servicing was hit by roughly $14 million of incremental MSR r...
- Record originations drove a standout quarter: fourth quarter revenue up 25% year over year with the highest funded volume Onity has ever originated.
- Originations strength came from both B2B and Consumer Direct, including expanded Ginnie Mae, closed-end seconds, and new non-QM product suite; Consumer Direct saw higher revenue per loan and larger average loan size.
- Servicing profitability was pressured by approximately $14 million of incremental MSR runoff in Q4, driven by FHA loan modification rule changes effective Oct 1 and a six-week government shutdown.
- +14 more takeaways
Fortis Inc. Q4 2025 Earnings Call - CAD 28.8B Five-Year Plan to Lift Rate Base 7% and Sustain Dividend Growth
Fortis used the call to sell scale and stability. Management delivered a clear growth story: CAD 5.6 billion of 2025 capital spending and a CAD 28.8 billion five-year plan that management says will ra...
- Fortis announced a CAD 28.8 billion five-year capital plan, its largest to date, focused on regulated transmission and distribution investments.
- Management expects the plan to increase rate base by approximately CAD 16 billion over five years, supporting average annual rate base growth of about 7%.
- Fortis invested CAD 5.6 billion in capital in 2025, and highlighted one of its best years for safety and reliability versus peers.
- +12 more takeaways
Organon Q4 2025 Earnings Call - Flat 2026 Outlook, Debt Reduction Takes Priority After JADA Sale
Organon closed 2025 with $6.2 billion of revenue and about $1.9 billion of adjusted EBITDA, and management is guiding to roughly the same results for 2026. The story is one of stabilization rather tha...
- Full year 2025 revenue was $6.2 billion, with adjusted EBITDA of about $1.9 billion; revenue was down 3% on both reported and ex-FX basis versus 2024.
- Organon is guiding to roughly flat results in 2026: about $6.2 billion of revenue and about $1.9 billion of adjusted EBITDA, pro forma for the JADA System divestiture and with an FX tailwind offsetting the loss of JADA revenue.
- Organon completed the divestiture of the JADA System in January for approximately $390 million in net proceeds, and management intends to apply proceeds to reduce net debt.
- +17 more takeaways
PHINIA Q4 2025 Earnings Call - Guides mid-single-digit 2026 growth with strong cash generation and shareholder returns
PHINIA closed 2025 with a resilient quarter and reiterated a capital-light, cash-first playbook for 2026. Q4 revenue was $889 million, Adjusted EBITDA $116 million, and adjusted EPS $1.18. Management ...
- Q4 2025 revenue $889 million, up 6.7% year over year; excluding FX and SEM contribution, revenue rose ~2.3% in the quarter.
- Adjusted EBITDA for Q4 was $116 million, a 13% margin, with adjusted EPS (ex-nonoperating items) of $1.18 vs. $0.71 a year ago.
- Full-year adjusted revenue ~ $3.5 billion, up ~3% year over year when excluding certain 2024 contract manufacturing; full-year adjusted EBITDA $478 million, essentially flat year over year.
- +12 more takeaways
Himax Technologies Q4 2025 Earnings Call - CPO and WiseEye Positioning Signal 2027 Revenue Levers, while 2026 Starts With a Trough
Himax closed Q4 with modest sequential revenue growth and a profitable quarter, but the call was dominated by a forward-looking storyline. Management paints 2026 as a trough quarter, expecting a rebou...
- Q4 revenue $203.1 million, up 2.0% sequentially, gross margin 30.4% in the quarter, and profit per diluted ADS reported in the call with conflicting figures (call notes both $0.036 and $0.086).
- Full year 2025 revenue $832.2 million, down 8.2% year-over-year; net profit $43.9 million, or $0.25 per diluted ADS, versus $79.8 million in 2024.
- Q4 segment mix: large display driver $21.7 million (10.7% of revenue); small/medium display drivers $139.1 million (68.5%); non-driver products $42.3 million (20.8%).
- +15 more takeaways
Nebius Group Q4 2025 Earnings Call - Capacity Sprint: Contracted Power Tops 2GW, Targeting >3GW and $7B-$9B ARR
Nebius closed 2025 with rapid scale and striking commercial momentum. Q4 revenue was $228 million, ARR exceeded guidance at $1.2 billion, and the core AI cloud business grew at hyperscale speed, with ...
- Q4 revenue $228 million, up 547% year over year and 56% quarter over quarter, with the company in mid-range of guidance.
- Annualized run rate revenue (ARR) for the core AI cloud hit $1.2 billion at year-end, above the high end of prior guidance.
- Core AI cloud revenue grew 830% year over year and 63% quarter over quarter, driving improved operating leverage.
- +15 more takeaways
Karyopharm Therapeutics Q4 2025 Earnings Call - Myelofibrosis Phase 3 SENTRI Readout in March Could Reframe Franchise
Karyopharm enters 2026 hinged on two late stage readouts, with the SENTRI phase 3 myelofibrosis top line expected in March and EXPORT-EC042 endometrial cancer data due mid-2026. Management argues seli...
- SENTRI phase 3 myelofibrosis top-line data expected in March 2026, company views this as the primary near-term value driver.
- EXPORT-EC042 phase 3 in P53 wild-type endometrial cancer remains on track for mid-2026 top-line data, with mandated dual antiemetics and a lower 60 mg selinexor dose versus prior trials.
- Selinexor 60 mg once weekly was selected for SENTRI based on phase 1 PK, efficacy and safety data, with company arguing 60 mg maximizes efficacy while remaining manageable.
- +12 more takeaways
West Pharmaceutical Services Q4 2025 Earnings Call - HVP components drive momentum, 2026 guided to 5%-7% organic growth
West closed 2025 with a clean set of beats and a clear thesis: higher-value product components are doing the heavy lifting. Q4 results outpaced expectations, driven by a 15% organic surge in HVP compo...
- Q4 revenue $805 million, reported growth 7.5%, organic growth 3.3%, beating management expectations.
- Full year 2025 net sales surpassed $3.0 billion with year-over-year organic growth of over 4%.
- HVP components were the standout: $390 million revenue in Q4, organic growth of 15.1%, and the primary driver of margin expansion.
- +12 more takeaways
Manulife Financial Corporation Q4 2025 Earnings Call - Record core earnings driven by double-digit new business CSM growth despite $9.5B GWAM outflows
Manulife closed 2025 with record core earnings, powered by double-digit new business CSM growth across insurance segments and strong performance in Asia and Global WAM, even as the wealth arm recorded...
- Manulife reported record core earnings for 2025, with core EPS up 8% for the year and Q4 core EPS up 9% year over year.
- New business CSM growth exceeded 20% in each insurance segment in 2025, and Manulife recorded its sixth consecutive quarter of >20% new business CSM growth.
- Global WAM posted elevated net outflows of $9.5 billion in Q4, driven by large U.S. retirement plan redemptions and higher participant withdrawals; gross flows rose 15% to $50 billion.
- +13 more takeaways